S. Scholl

发表

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

N. Robert, D. Tripathy, S. Shak, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.

S. Scholl, R. Bauer, Jörg P Müller, 2012, Blood.

phosphatase DEP-1 / PTPRJ oxidative inactivation of the tumor suppressor protein-tyrosine Cell transformation by FLT 3 ITD in acute myeloid leukemia involves

S. Scholl, R. Bauer, Jörg P Müller, 2012 .

Isoform localization of Dectin‐1 regulates the signaling quality of anti‐fungal immunity

S. Scholl, Kerstin Hünniger, O. Kurzai, 2017, European journal of immunology.

Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.

S. Scholl, J. Clement, K. Höffken, 2005, The Journal of laboratory and clinical medicine.

Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells

S. Scholl, R. Klinger, F. Böhmer, 2004, Journal of Cancer Research and Clinical Oncology.

Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations

S. Scholl, A. Hochhaus, A. Klink, 2011, Annals of Hematology.

Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia

S. Scholl, A. Hochhaus, T. Rachow, 2014, Genes and Immunity.

Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia

S. Scholl, A. Hochhaus, U. Schnetzke, 2013, Annals of Hematology.

EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia

H. Einsele, T. Brümmendorf, A. Krämer, 2020, Haematologica.

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients

S. Scholl, A. Hochhaus, H. Sayer, 2016, Journal of Cancer Research and Clinical Oncology.

Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT

S. Scholl, K. Pachmann, K. Höffken, 2005, Bone Marrow Transplantation.

ATRA can enhance apoptosis that is induced by Flt3 tyrosine kinase inhibition in Flt3-ITD positive cells.

S. Scholl, J. Clement, K. Höffken, 2006, Leukemia research.

Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome

S. Scholl, A. Reiter, A. Hochhaus, 2011, Annals of Hematology.

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

W. Hiddemann, H. Einsele, K. Metzeler, 2022, Journal of Hematology & Oncology.

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

K. Döhner, R. Schlenk, H. Döhner, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex-Disaggregated Analysis of Biology, Treatment Tolerability, and Outcome of Multiple Myeloma in a German Cohort

S. Scholl, A. Hochhaus, H. Sayer, 2022, Oncology Research and Treatment.

Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase γ

S. Scholl, R. Wetzker, J. Clement, 2008, Journal of Cancer Research and Clinical Oncology.

Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

H. Einsele, T. Brümmendorf, A. Krämer, 2022, Journal of Hematology & Oncology.

Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia

S. Scholl, C. Thiede, A. Hochhaus, 2022, Journal of Cancer Research and Clinical Oncology.

Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review

S. Scholl, A. Hochhaus, H. Sayer, 2014, European journal of haematology.

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

K. Götze, M. Fey, W. Brugger, 2012, Leukemia.

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis

H. Einsele, T. Brümmendorf, S. Scholl, 2021, Leukemia & lymphoma.

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

S. Scholl, C. Thiede, A. Hochhaus, 2021, Journal of Cancer Research and Clinical Oncology.

Impact of FLT3-ITD diversity on response to induction chemotherapy in patients with acute myeloid leukemia

M. Walther, S. Scholl, A. Hochhaus, 2017, Haematologica.

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia

S. Scholl, B. Gruhn, A. Hochhaus, 2016, PloS one.

Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia

S. Scholl, A. Hochhaus, U. Schnetzke, 2015, Journal of Cancer Research and Clinical Oncology.

Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy

S. Scholl, A. Hochhaus, H. Sayer, 2021, Journal of Cancer Research and Clinical Oncology.

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

J. Esteve, G. Garcia-Manero, U. Borate, 2020 .

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

K. Döhner, H. Döhner, V. Gaidzik, 2021, Blood Cancer Journal.

Impact of induction chemotherapy with intermediate-dosed cytarabine and subsequent allogeneic stem cell transplantation on the outcome of high-risk acute myeloid leukemia

S. Scholl, A. Hochhaus, H. Sayer, 2021, Journal of Cancer Research and Clinical Oncology.

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

H. Einsele, T. Brümmendorf, M. Görner, 2022, Journal of Cancer Research and Clinical Oncology.

The E3 ubiquitin ligase TRAF2 can contribute to TNF-α resistance in FLT3-ITD-positive AML cells.

S. Scholl, A. Hochhaus, Jörg P Müller, 2013, Leukemia research.

The E3 ubiquitin ligase TRAF6 inhibits LPS-induced AKT activation in FLT3-ITD-positive MV4-11 AML cells

S. Scholl, A. Kuhn, A. Hochhaus, 2013, Journal of Cancer Research and Clinical Oncology.

Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD)

S. Scholl, A. Hochhaus, H. Sayer, 2013, Journal of Cancer Research and Clinical Oncology.

Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies

S. Scholl, A. Hochhaus, T. Ernst, 2017, Journal of Cancer Research and Clinical Oncology.

Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation

K. Kliche, S. Scholl, J. Clement, 2004, Journal of Cancer Research and Clinical Oncology.

Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.

S. Scholl, J. Clement, K. Höffken, 2005, Leukemia research.

Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

J. Esteve, G. Garcia-Manero, U. Borate, 2019, Blood.

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup.

W. Hiddemann, K. Döhner, R. Schlenk, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary cutaneous aspergillosis – an uncommon opportunistic infection Review of the literature and case presentation

P. Elsner, S. Scholl, U. Hipler, 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

HHV-6 encephalitis in a non-transplanted adult acute myeloid leukemia patient

S. Scholl, A. Hochhaus, J. Zinke, 2021, Annals of Hematology.

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

H. Einsele, T. Brümmendorf, S. Scholl, 2023, Blood Cancer Journal.

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.

H. Einsele, T. Brümmendorf, A. Krämer, 2021, Blood advances.

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

S. Scholl, A. Hochhaus, U. Schnetzke, 2021, Cancers.

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

S. Scholl, D. Michel, T. Stamminger, 2019, Mediterranean journal of hematology and infectious diseases.

Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

K. Döhner, R. Schlenk, H. Döhner, 2021, Blood.

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression

S. Scholl, J. Lennartsson, C. Müller-Tidow, 2012, Cell Communication and Signaling.

Clinical implications of molecular genetic aberrations in acute myeloid leukemia

S. Scholl, K. Höffken, H. Sayer, 2009, Journal of Cancer Research and Clinical Oncology.

Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment

S. Scholl, A. Hochhaus, H. Sayer, 2017, Journal of Cancer Research and Clinical Oncology.

Ponatinib may overcome resistance of FLT3‐ITD harbouring additional point mutations, notably the previously refractory F691I mutation

S. Scholl, F. Heidel, T. Fischer, 2012, British journal of haematology.

Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation

S. Scholl, A. Hochhaus, H. Sayer, 2011, Journal of Cancer Research and Clinical Oncology.

Safety and impact of donor‐type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch

S. Scholl, K. Höffken, H. Sayer, 2005, Transfusion.

First Report of a Prospective Randomised Controlled Trial of Recombinant Human Erythropoietin after Allogeneic Blood Stem Cell Transplantation.

S. Scholl, H. Sayer, K. Hoeffken, 2004 .

Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

D. Niederwieser, S. Scholl, C. Junghanss, 2021, Annals of Hematology.

Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity

S. Scholl, C. Junghanss, A. Hochhaus, 2020, Bone Marrow Transplantation.

Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 mutations in acute myeloid leukaemia.

S. Scholl, O. Landt, J. Clement, 2007, Leukemia research.

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia.

H. Einsele, T. Brümmendorf, A. Krämer, 2019, Blood.

CEBPA Mutations in 4708 Patients with Acute Myeloid Leukemia - Differential Impact of bZIP and TAD Mutations on Outcome.

H. Einsele, T. Brümmendorf, A. Krämer, 2021, Blood.

Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

J. Esteve, G. Garcia-Manero, U. Borate, 2021, Blood.

Flt3-ITD mutations can generate leukaemia specific neoepitopes: Potential role for immunotherapeutic approaches

S. Scholl, K. Höffken, A. Kaufmann, 2006, Leukemia & lymphoma.

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

D. Niederwieser, S. Scholl, C. Junghanss, 2015, Journal of Cancer Research and Clinical Oncology.

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors

S. Scholl, K. Höffken, H. Sayer, 2004, Bone Marrow Transplantation.

Distinct reconstitution of neutrophil functions after allogeneic peripheral blood stem cell transplantation

S. Scholl, K. Höffken, H. Sayer, 2007, Journal of Cancer Research and Clinical Oncology.

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia

S. Scholl, K. Höffken, V. Scheble, 2008, European journal of haematology.

Sustained expression of nucleophosmin (NPM1) mutation at late relapse presenting as isolated myeloid sarcoma in a patient with acute myeloid leukemia

S. Scholl, K. Höffken, L. Mügge, 2007, Annals of Hematology.

Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

W. Hiddemann, B. Dörken, A. Krämer, 2023, Annals of Hematology.

Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML)

S. Scholl, A. Hochhaus, P. Rosée, 2014, Journal of Cancer Research and Clinical Oncology.

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

H. Einsele, T. Brümmendorf, A. Krämer, 2020, Blood.

Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

W. Hiddemann, A. Krämer, D. Niederwieser, 2016 .

The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML

G. Martinelli, A. Zelent, S. Scholl, 2019, Leukemia.

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

R. Schlenk, H. Einsele, A. Ho, 2021, Haematologica.

Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance

S. Scholl, F. Heidel, Joanna M. Kirkpatrick, 2021, Cells.

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments

S. Scholl, F. Heidel, U. Schnetzke, 2020, Cells.

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.

K. Götze, M. Lübbert, P. Dreger, 2017, European journal of cancer.

Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma

S. Scholl, A. Hochhaus, U. Schnetzke, 2022, Bone Marrow Transplantation.

Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

G. Lenz, S. Raffel, S. Scholl, 2021, Blood.

Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

J. Esteve, G. Garcia-Manero, U. Borate, 2021, Blood.

Loss-of-Function Mutations of BCOR Are an Independent Marker of Adverse Outcomes in Intensively Treated Patients with Acute Myeloid Leukemia

H. Einsele, T. Brümmendorf, A. Krämer, 2021, Cancers.

Measurement of piperacillin plasma concentrations in cancer patients with suspected infection

P. Schlattmann, S. Scholl, S. Bremer-Streck, 2017, Infection.

Allogeneic blood stem cell transplantation in advanced chronic myeloid leukemia--high response rate associated with increased chronic graft-versus-host disease.

S. Scholl, K. Höffken, H. Sayer, 2003, Haematologica.

Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML

T. Cotter, S. Scholl, J. Stanicka, 2017, Oncotarget.

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells

Jörg Lässig, R. Moriggl, S. Scholl, 2016, Leukemia.

Acute Abdomen by Varicella Zoster Virus Induced Gastritis after Autologous Peripheral Blood Stem Cell Transplantation in a Patient with Non-Hodgkin’s Lymphoma

S. Scholl, K. Höffken, M. Hocke, 2006, Acta Haematologica.

SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders

S. Scholl, F. Heidel, A. Hochhaus, 2020, Leukemia.

Lower gastrointestinal bleeding in a patient with Crohn’s disease and plasma cell leukemia in remission

S. Scholl, A. Hochhaus, K. Katenkamp, 2015, Annals of Hematology.

Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

K. Götze, M. Fey, W. Brugger, 2010 .

The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey

A. Scherag, S. Scholl, A. Hochhaus, 2019, Annals of Hematology.

Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

G. Lenz, S. Raffel, S. Scholl, 2022, Blood.

Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.

S. Scholl, A. Reiter, A. Neubauer, 2009 .

Factors Influencing Complete Remission (CR) Rate in Patients ≥ 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study

W. Hiddemann, D. Niederwieser, S. Scholl, 2012 .

A Mosquito Bite with Devastating Complications in an Immunocompromised Patient

S. Scholl, T. Dönicke, A. Hochhaus, 2019, Case Reports in Oncology.

UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

H. Einsele, T. Brümmendorf, S. Scholl, 2023, Blood cancer journal.

Melphalan 200 mg/m2 does not increase toxicity and improves survival in comparison to reduced doses of melphalan in multiple myeloma patients

P. Rucci, S. Scholl, A. Hochhaus, 2020, Bone Marrow Transplantation.

Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

K. Döhner, R. Schlenk, H. Döhner, 2020 .

Staphylococcus intermedius infection with splenic abscesses in a patient with acute lymphoblastic leukemia

S. Scholl, A. Hochhaus, U. Schnetzke, 2023, Annals of Hematology.

Drug-induced lymphadenopathy with eosinophilia and renal failure mimicking lymphoma disease: dramatic onset of DRESS syndrome associated with antibiotic treatment

S. Scholl, M. Freesmeyer, A. Hochhaus, 2011, Annals of Hematology.

Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

K. Döhner, R. Schlenk, H. Döhner, 2016 .

Functional acute liver failure after treatment with pegylated asparaginase in a patient with acute lymphoblastic leukemia: potential impact of plasmapheresis

S. Scholl, A. Hochhaus, U. Schnetzke, 2016, Annals of Hematology.

MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study

G. Garcia-Manero, U. Borate, E. Traer, 2021 .

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Different clones of acute leukemia after successful treatment of Hodgkin’s disease

S. Scholl, A. Hochhaus, U. Schnetzke, 2014, Annals of Hematology.

Specific pattern of protein expression in acute myeloid leukemia harboring FLT3-ITD mutations

S. Scholl, K. Höffken, F. von Eggeling, 2007, Leukemia & lymphoma.

Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients

S. Scholl, A. Hochhaus, H. Sayer, 2018, Blood.

Successful treatment of neutropenic MRSA bacteremia with septic superior vena cava thrombus and cerebral embolism using high-dose daptomycin

Mathias W Pletz, S. Scholl, A. Hochhaus, 2015, Annals of Hematology.

Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia.

L. Bullinger, M. Heuser, V. Vasioukhin, 2023, Leukemia.

Expression of protein-tyrosine phosphatases in Acute Myeloid Leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression

S. Scholl, J. Lennartsson, C. Müller-Tidow, 2012, Cell Communication and Signaling.

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial

R. Schlenk, A. Krämer, S. Scholl, 2023, Haematologica.

Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5‐azacytidine and literature review

S. Scholl, A. Hochhaus, H. Sayer, 2014, European journal of haematology.

A 19-year-old patient with atypical chronic myeloid leukemia

T. Haferlach, S. Scholl, H. Kreipe, 2020, Annals of Hematology.